Candide Solution for external use 1%, 20 ml
Category
Antifungal
Scope of the drug
Dermatology
Release form
Solution
Manufacturer country
India
Package quantity, pcs
one
Candide rr d / nar.
approx.
1% 20ml No. 1
Name ENG
CANDID
Clinical and pharmacological group
Antifungal drug for external use
ATX code
Clotrimazole
Dosage
1% x 20ml
Structure
1 ml of solution contains:
Active ingredient: clotrimazole 10 mg
Excipients: propylene glycol - 495 mg
glycerin - 495 mg.
Indications
Dermatophytosis of the head (including the face), body, legs
mycosis of nails
versicolor versicolor
candidiasis of the skin
candidal paronychia
candidal vulvitis
candidal balanitis
candidiasis of the external genital organs and the anus
fungal diaper dermatitis
erythrasma.
Storage conditions and periods
In a dark place at a temperature of 2-25 degrees.
Expiration date: 3 years
INN / Active ingredient
clotrimazole
Contraindications
Hypersensitivity
specific skin lesions (including tuberculosis, chickenpox, herpes simplex, measles, syphilis)
skin reactions at the vaccination site.
Specifications
Category
Antifungal
Scope of the drug
Dermatology
Release form
Solution
Manufacturer country
India
Package quantity, pcs
one
Scope of application
Dermatology
Minimum age from
18 years
Way of introduction
Outwardly
,
On the skin
Vacation conditions
Without recipe
Volume, ml.
20 ml
Brand name
Glenmark Pharmaceuticals LTD IN
,
Glenmark
The amount of the dosage form in the primary package
20 ml
Primary packaging type
Bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antifungal agent
Anatomical and therapeutic characteristics
D01AC01 Clotrimazole
Dosage form
Solution for external use
Packaging
Box
Expiration date in days
1095
Dosage (volume) of the substance in the preparation
1 ml: clotrimazole 10 mg
The target audience
Adult
Package weight, g
thirty
Mode of application
:
Outwardly.
Apply the solution to previously washed (using soap with a neutral pH value) and dried affected skin areas 2 times a day.
The duration of treatment depends on the severity of the disease, the localization of pathological changes and the effectiveness of therapy.
Treatment of dermatomycosis is carried out at least 4 weeks, pityriasis versicolor - 1–3 weeks.
In case of fungal diseases of the skin of the legs, therapy is recommended to continue for at least 2 weeks after the symptoms of the disease have been eliminated.